Supplement to prospectus
Immunicum publishes supplement to prospectus for rights issue
Immunicum AB (publ) (”Immunicum”) has today published a supplement to the prospectus dated May 12, 2014 prepared in connection with the ongoing rights issue. The supplement to the prospectus follows from the press release “IMMUNICUM REPORTS PRELIMINARY REGRESSION DATA AFTER ADD-ON THERAPY WITH TYROSINE KINASE INHIBITORS AND CONTINUED COMPELLING SURVIVAL DATA FROM THE FORMALLY COMPLETED PHASE I/II-STUDY IN RENAL CELL CARCINOMA” published on May 21, 2014.
Read the supplement to prospectus (in Swedish) here: Immunicum tilläggsprospekt 2014